A Randomized, Parallel, Open-Label Study to Compare the Pharmacokinetics of Ipilimumab (BMS-734016) Process C to Process B in Subjects With Advanced Melanoma

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Pharmacokinetics of ipilimumab Process B and Process C derived from serum concentration versus time data

Outcome Time Frame:

Up to Week 4 (Day 22) on treatment

Safety Issue:

No

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

United States: Food and Drug Administration

Study ID:

CA184-087

NCT ID:

NCT00920907

Start Date:

August 2009

Completion Date:

October 2012

Related Keywords:

• Advanced Melanoma
• Melanoma